摘要
目的:
1.建立一套高效的无血清体外制备DCs疫苗的方法,为DCs疫苗的临床应用提供实验依据。
2.探讨DCs对CIK增殖和杀伤肝癌细胞的影响。
方法:
1.采集脐血,分离其中的单个核细胞,用无血清DCs培养基(SFM)/含5%胎牛血清的RPMI-1640培养基(SM),并添加rhGM-CSF、rhIL-4联合诱导单个核细胞分化为未成熟DCs,第5天添加肝癌细胞冻融抗原,TNF-α等促成熟因子,第7天收获成熟DCs,以倒置显微镜观察DCs的细胞形态,流式细胞仪测定Des表面标志物的表达;并从细胞形态和表面标志物等方面比较用无血清DCs培养基(SFM)/含5%胎牛血清的RPMI-1640培养基(SM)培养的DCs。
2.用细胞因子γ-IFN、IL-2、CD3-Ab、IL-1a诱导脐血单个核细胞为CIK,第7天DCs和CIK共同培养。采用MTT法测定无血清培养基和含5%胎牛血清的培养基产生的DCs刺激CIK的促增殖效应和DC-CIK对肝癌细胞的杀伤效应。
结果:
1.无论采用无血清树突状细胞培养基(SFM)还是含5%胎牛血清的RPMI-1640培养基,脐血来源的单核细胞在细胞因子rhGM-CSF、rhIL-4、TNF-α的诱导下,并负载7721肝癌细胞冻融抗原后,均能分化成为具有典型形态和表型的成熟DCs,流式结果显示:采用无血清培养基培养的DCs表面标志物表达水平为(%):CD1a 56.6±3.8、CD11c 64.5±4.3、CD14 19.5±1.8、CD4077.8±7.5、CD83 70.8±5.1、CD86 76.5±6.3、HLA-DR 91.5±3.5;采用5%胎牛血清的RPMI-1640培养基培养的SM-DC表面标志物表达水平为(%):CD1a 59.3±5.1、CD11c 59.6±6.2、CD14 20.1±2.2、CD40 75.6±6.4、CD83 65.2±4.4、CD8680.4±6.9、HLA-DR 94.5±2.8;两组DCs的表面标志均无差别,(P＞0.05)。
2.混合淋巴细胞反应结果:DCs刺激CIK的刺激指数为:无血清DCs培养基组2.01±0.22,含血清培养基DCs组2.31±0.24;统计分析表明:不同培养基培养的DCs,在促进淋巴细胞增殖作用中无差别,均能有效地刺激CIK增殖,(P＞0.05)。
3.杀伤实验结果:DCs激活CIK对肝癌细胞的杀伤率为(%):无血清DCs培养基组SFMDC-CIK 74.5±7.5,含血清培养基组SMDC-CIK 77.9±6.0,单一CIK 54.1±4.9,统计分析表明:①SM-DC和SFM-DC激活的CIK对肝癌细胞的杀伤率无明显差别,(P＞0.05);②SM-DC和SFM-DC激活的CIK对肝癌细胞的杀伤率均高于未被DCs激活的CIK,(P＜0.05)。
结论:
1.我们初步建立了一套体外无血清制备DCs的方法;无血清树突状细胞培养基在添加细胞因子rhGM-CSF 100ng/ml、rhIL-4、50ng/ml、TNF-α50ng/ml及肝癌抗原后,能够诱导脐血单个核细胞分化为具有典型形态和高度表达DCs表面标志的成熟树突状细胞。
2.SM-DC和SFM-DC均能有效地刺激CIK增殖及提高其抗肿瘤作用,DC-CIK治疗肿瘤将具有良好的应用前景。
Objectives:
1.To establish a highly effective method for preparing the DCs vaccine in serum-free medium in vitro,and provid experimental proof for the clinical antitumor therapy.
2.To explore the effect of DCs on the proliferation of CIK and the cytotoxicity of CIK against hepatocellular carcinoma cells.
Methods:
1.The mononuclear cells separated from cord blood were induced to differentiate into the immature DC by rhGM-CSF and rhIL-4 in serum-free medium (SFM)or 5%fetal calf serum RPMI-1640 medium(SM).TNF-αand the Freeze-thaw lysates of hepatocellular carcinoma cells were was added on the 5th day. On the 7th day,these cells were harvested and identified with light microscope and flow cytometry(FCM).Then,the morphology and surface markers of SM-cultured DCs(SM-DCs)and SFM-derived DCs(SFM-DCs)was compared.
2.The mononuclear cells from cord blood were induced to differentiate into CIK by cytokines IFN-γ,IL-2,CD3-Ab,IL-la.DCs were co-cultured with autologous CIK cells on the 7th day.Then,the proliferation and the cytotoxicity of CIK stimulated with DCs was examined by methyl thiazoly tetrazolium(MTT).
Results:
1.Mononuclear cells separated from the cord blood could be induced into typical and phenotypic DC s with the compatibility of such cellular factors as rhGM-CSF, IL-4,TNF-α,and pulsed antigen.The flow cytometry detection showed:the expression level(%)of cell surface markers of DCs cultured on the SFM-DC:CD1a 56.6±3.8,CD11c 64.5±4.3,CD14 19.5±1.8,CD40 77.8±7.5,CD83 70.8±5.1,CD86 76.5±6.3 HLA-DR 91.5±3.5;The expression level(%)of cell surface markers on the SM-DC:CD1a 59.3±5.1,CD11c 59.6±6.2,CD14 20.1±2.2,CD40 75.6±6.4, CD83 65.2±4.4,CD86 80.4±6.9,HLA-DR 94.5±2.8;The levels of surface markers were not significantly different between SFM-DC and SM-DC,(p＞0.05).
2.The results of mixed lymphocyte reaction:The average stimulator index(SI) of CIK actvavted by SFM-DC:2.01±0.22;The average stimulator index(SI)of CIK actvavted by SM-DC:2.31±0.24.The difference of the stimulator index(SI)between SFMDC and SMDC was not significant and they could effectively activate CIK cells to proliferate.
3.The results of cytotoxicity assay:The cytotoxicity to hepatocellular carcinoma cells:the cytotoxicity of SFMDC-CIK 74.5±7.5,the cytotoxicity of SMDC-CIK 77.9±6.0,the cytotoxicity of SMDC-CIK 54.1±4.9;The statistical analysis shows:①The difference of the cytotoxicity between SFMDC-CIK and SMDC-CIK was not significantly,(p＞0.05);②SFMDC-CIK and SMDC-CIK possessed higher ability to lyse hepatoma cells than inactivated CIK,(p＜0.05).
Conclusion:
1.We Preliminarily established a method for preparing the DCs vaccine in serum-free medium in vitro.In serum-free DCs medium with rhGM-CSF 100ng/ml, rhIL-4 50ng/ml,TNF-α50ng/ml,mononuclear ceils from the cord blood could be induced into the Clinical grade DCs with typical modality and Cell surface markers
2.Both SFM-DC and SM-DC could Effectively activate CIK cells to have higher proliferative and anti-tumor activity,and DC-CIK will have a good prospect in the treatment of tumors.
引文
[1] KULIK LM. Advancements in hepatocellular carcinoma[J]. Curr Opin Gastro-enterol. 2007; 23(3):268-274.
[2] Zimmerman MA, Ghobrial RM, Tong MJ et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators[J]. Arch Surg.2008; 143(2): 182-188.
[3] Kim RD, Reed AI, Fujita S, et al. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg[J].2007;205 (1): 108-123.
[4] Chen YX, Man K, Ling GS, et al. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10[J]. J Immunol. 2007; 179(9): 6009-6015.
[5] Beckebaum S, Zhang X, Chen X, et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets[J]. Clin Cancer Res. 2004;10(21): 7260-7269.
[6] Kakumu S, Ito S, Ishikawa T, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection[J]. J Gastroenterol Hepatol. 2000; 15(4):431-436.
[7] Marten A, Ziske C, Schottker B et al.Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations [J]. J Immunother. 2001; 24(6): 502-510.
[8] Steinman RM, Cohn ZA. Identification of a novel cell type in tissue distribution. J ExpMed[J]. 1973 ;137:1142-1162.
[9] Wu L, Dakic A. Development of dendritic cell system. Cell Mol Immunol[J]. 20 04; 1: 112-118.
[10] Rissoan MC,Soumelis V,Kadowaki N.Reciprocal control of T helper cell and dendritic cell differentiation[J].Science.l999;283(5405):1183-1186.
[11] Reinhard G,Marten A,Kiske SM ,et al.Generation of dendritic cell-based vaccines for cancer therapy[J]. Br J Cancer.2002;86(10):1529-1533.
[12] Banchereau J. Steinman R.Dendritic cells and the control of immunity[J]. Nature. 1998; 392:245-252.
[13] Lukacs-Kornek V, Engel D, Tacke F, Kurts C. The role of chemokines and their receptors in dendritic cell biology[J].Front Biosci.2008; 13:2238-52.
[14] Savina A, Amigorena S. Phagocytosis and antigen presentation in dendritic cells[J]. Immunol Rev. 2007;219:143-56.
[15] Sato K, Fujita S. Dendritic cells: nature and classification[J]. Allergol Int. 2007;56(3):183-91.
[16] Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function[J]. Cytokine Growth Factor Rev. 2008;19(1):65-77.
[17] Ullrich E, Menard C, Flament C, et al. Dendritic cells and innate defense against tumor cells[J]. Cytokine Growth Factor Rev. 2008; 19(1): 79-92.
[18] Nencioni A, Grunebach F, Schmidt SM, et al. The use of dendritic cells in cancer immunotherapy[J]. Crit Rev Oncol Hematol. 2008;65(3): 191-199.
[19] Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immuno-therapy[J]. Adv Cancer Res. 2008;99:363-407.
[20] Chen S,Akbar SM,Tanimoto K,et al.Absence of CD83 Positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma:Relevance to hepatocarcinogenesis [J].Cancer Lett.2000;148(1):49-57.
[21] Cai XY,CAO Q,Qiu SJ,et al.Dendritic cell infiltration and prognosis of human hepatocellular carcinoma[J]. J Cancer Res Clin Oncol.2006;132(5):293-301.
[22] Tang TJ, Vukosavljevic D, Janssen HL, et al.Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcino-ma[J].Hum Pathol. 2006;37(3):332-338.
[23] Kadowaki N. Dendritic cells: a conductor of T cell differentiation[J]. Allergol Int. 2007;56(3):193-199.
[24] Wu L, Liu YJ. Development of dendritic-cell lineages [J]. Immunity. 2007;26(6): 741-750.
[25] Jacobs B, Wuttke M, Papewalis C,et al. Dendritic cell subtypes and in vitro generation of dendritic cells[J]. Horm Metab Res. 2008;40(2):99-107.
[26] Hochrein H, O'Keeffe M. Dendritic cell subsets and toll-like receptors[J]. Handb Exp Pharmacol. 2008;(183):153-179.
[27] Lin KW, Jacek T, Jacek R. Dendritic cells heterogeneity and its role in cancer immunity[J]. J Cancer Res Ther. 2006;2(2):35-40.
[28 Dominguez-Soto A, Corbi AL. Myeloid dendritic cell lectins and their role in immune responses[J]. Curr Opin Investig Drugs. 2007;8(11):910-920.
[29] Ueno H, Klechevsky E, Morita R, et al. Dendritic cell subsets in health and dise-ase[J]. Immunol Rev. 2007;219:118-142.
[30] Lee WC, Chiang YJ, Wang HC, et al. Functional impairment of dendritic cells caused by murine hepatocellular carcinoma[.T].J Clin Immunol.2004;24(2):145-154.
[31] Ninomiya T, Akbar SM, Masumoto T , et al. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma[J]. J Hepatol. 1999;31 (2):323-331.
[32] Um SH, Mulhall C, Alisa A, et al. Alpha-fetoprotein impairs APC function and induces their apoptosis[J]. J Immunol. 2004; 173(3): 1772-1778.
[33] Proudfoot O, Pouniotis D, Sheng KC,et al. Dendritic cell vaccination[J]. Expert Rev Vaccines.2007;6(4):617-633.
[34] Steinman RM, Banchereau J. Taking dendritic cells into medicine [J]. Nature. 2007 27;449(7161):419-426.
[35] Lee WC, Wang HC, Hung CF, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial[J]. J Immun- other. 2005;28(5):496-504c
[36] Butterfield LH, Ribas A, Dissette VB ,et al.A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides[J]. Clin Cancer Res. 2006;12(9):2817-2825.
[37] Chi KH, Liu SJ, Li CP, Kuo HP, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma[J]. J Immunother. 2005;28(2):129-135.
[38] Nakamoto Y, Mizukoshi E, Tsuji H, et al.Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety[J]. Clin Exp Immunol. 2007;147(2):296-305.
[39] Sumpter TL, Abe M, Tokita D, Thomson AW. Dendritic cells, the liver, and transplantation[J].Hepatology.2007;46(6):2021-31.
[40]Hsu W,Shu SA,Gershwin E,Lian ZX.The current immune function of hepatic dendritic cells[J].Cell Mol Immunol.2007;4(5):321-328.
[41]Lau AH,Thomson AW.Dendritic cells and immune regulation in the liver[J].Gut.2003;52(2):307-314.
[42]Kawakami Y,Fujita T,Kudo C,et al.Dendritic cell based personalized immunotherapy based on cancer antigen research[J].Front Biosci.2008;13:1952-1958.
[43]Tacken PJ,de Vries IJ,Torensma R,et al.Dendritic-cell immunotherapy:from ex vivo loading to in vivo targeting[J].Nat Rev Immunol.2007;7(10):790-802.
[44]吴尘轩,杜智;树突状细胞与肝细胞癌免疫治疗[J].国际肿瘤学杂志,2006,33(5):366-369.
[45]Gilliet M,Liu YJ.Human plasmacytoid-derived dendritic cells and the induction of T-regulatory ceils[J].Hum Immunol.2002;63(12):1149-55.
[46]Morse MA,Zhou LJ,Tedder TF,et al.Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor,interleukin-4,and tumor necrosis factor-alpha for use in cancer immunotherapy[J].Ann Surg.1997;226(1):6-16.
[47]Napoletano C,Pinto D,Bellati F,et al.A comparative analysis of serum and serum-free media for generation of clinical grade DCs[J].J Immunother.2007;30(5):567-576.
[48]Kufner S,Zitzelsberger H,Kroell T,et al.Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia:a methodological approach under serum-free culture conditions[J].Scand J Immunol.2005;62(1):86-98.
[49]Kufner S,Zitzelsberger H,Kroell T,et al.Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia:a methodological approach under serum-free culture conditions[J].Scand J Immunol.2005;62(1):75-85.
[50]Elias M,van Zanten J,Hospers GA,et al.Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy[J].J Clin Apher.2005;20(4):197-207.
[51]Schmidt-Wolf IG,Negrin RS,Kiem HP,et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J].J Exp Med.1991;174(1):139-149.
[52]Terabe M,Berzofsky JA.NKT cells in immunoregulation of tumor immunity:a new immunoregulatory axis[J].Trends Immunol.2007;28(11):491-496.
[53]Bendelac A,Savage PB,Teyton L.The biology of.NKT cells[J].Annu Rev Immunol.2007;25:297-336.
[54]Linn YC,Hui KM.Cytokine-induced killer cells:NK-like T cells with cytotolytic specificity against leukemia[J].Leuk Lymphoma.2003;44(9):1457-1462.
[55]Gonzalez-Carmona MA,Mairten A,et al.Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells[J].Liver Int.2006;26(3):369-79.
[56]Kim HM,Lim J,Yoon YD,et al.Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.Int Immunopharmacol[J].2007 15;7(13):1793-1801.
[57]李世俊 张连生 柴晔 等树突状细胞与细胞因子诱导的杀伤细胞共培养对多药耐药肿瘤细胞系的杀伤活性[J].中华肿瘤杂志,2007;29(10):733-737.
[58]Kim HM,Lim J,Park SK,et al.Antitumor activity of cytokine-induced killer cells against human lung cancer.Int Immunopharmacol[J].2007 15;7(13):1802-1807.
[59]Introna M,Franceschetti M,Ciocca A,et al.Rapid and massive expansion of cord blood-derived cytokine-induced killer cells:an innovative proposal for the treatment of leukemia relapse after cord blood transplantation[J].Bone Marrow Transplant.2006;38(9):621-627.
[1]Kulik LM.Advancements in hepatocellular carcinoma[J].Cur Opin Oastroentterol,2007,23(3):268-274.
[2]Steinman RM,Cohn ZA.Identification of a novel cell type in tissue distribution[J].J Exp Med,1973,137:1142-1162.
[3]Banchereau J,Steinman RM.Dendritic cells and the control of immunity[J].Nature,1998,392:245-252.
[4]Wu L,Dakic A.Development of dendritic cell system[J].Cell Mol Immunol,2004,1:112-118.
[5]Rissoan MC,Soumelis V,Kadowaki N.Reciprocal control of T helper cell and dendritic cell differentiation[J].Science,1999,283(5405):1183-1186
[6]Reinhard G,Marten A,Kiske SM,et al.Generation of dendritic cell-based vaccines for cancer therapy[J].Br J Cancer,2002,86(10):1529-1533.
[7]Chert S,Akbar SM,Tanimoto K,et al.Absence of CD83 Positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma:Relevance to hepatocarcinogenesis[J].Cancer Lett,2000,148(1):49-57.
[8]CAI XY,CAO Q,QIU SJ,et al.Dendritic cell infiltration and prognosis of human hepatocellular carcinoma[J].J Cancer Res Clin Oncol,2006,132(5):293-301.
[9]TANG TJ,VUKOSAVLJEVIC D,JANSSEN HL,et al.Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma[J].Hum Pathol,2006,37(3):332-338.
[10]Lee WC,Chiang YJ,Wang HC,et al.Functional impairment of dendritic cells caused by murine hepatocellular carcinoma[J].J Clin Immunol,2004,24(2):145-154.
[11]NINOMIYA T,AKBAR SM,Masumoto T,et al.Dendritic ceils with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma[J].J Hepatol,1999,31(2):323-31.
[12]Beckebaum S,Zhang X,Chen X,et al.Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets[J].Clin Cancer Res,2004,10(21):7260-7269.
[13]Um SH,Mulhall C,Alisa A,et al.Alpha-fetoprotein impairs APC function and induces their apoptosis[J].J Immunol,2004,173(3):1772-1778.
[14]CAO DY,Yang JY,Dou KF,et al.alpha-fetoprotein and interleukin-18 genemodified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro[J].Hum Immunol,2007,68(5):334-341.
[15]Zhang L,Zhang H,Liu W,et al.Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2total RNA[J].Cell Immunol,2005,238(1):61-66.
[16]HAYASHI T,NAKAO,KNAGAYAMA Y,et al.Vaccination with dendritic cells pulsed with apoptotic cells elicits effective antitumor immunity in murine hepatoma models[J].Int J Oncol,2005,26(5):1313-1319.
[17]Liang CM,Ye SL,Zhong CP,et al.Treatment of non resectable hepatocellular carcinoma with autologous tumor-pulse dendritic cells[J].J Gastroenterol Hepetol,2002,17(8):889-896.
[18]IWASHITA Y,TAHARA K,GOTO S,et al.A phase I study of autologous dendritic cell-based immuneotherapy for patients with unresectable primary liver cancer[J].Cancer Immunol Immunother,2003,52(3):155-161.
[19]Lee WC,Wang HC,Hung CF,et al.Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells:a clinical trial[J].J Immunother.2005,28(5):496-504.
[20]高建,陈敏,任红.肝癌细胞裂解物致敏的树突状细胞瘤苗预防肝癌术后转移复发.中华肝脏病杂志[J].2005,13(6):432-435.
[21]Homma S,TodaG,GongJ,et al.Preventive antitumor activity against hepatocellular carcinoma(HCC)induced by immunization with fusions of dendritic cells and HCC cells in mice[J].J Gastroenterol,2001,36(11):764-771
[22]Zhang HM,Zhang LW,Liu WCC,et al.Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma[J].Cytotherapy,2006,8(6):580-588.
[23]Butterfield LH,Ribas A,Dissette VB,et al.A phase Ⅰ/Ⅱ trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alphafetoprotein peptides[J].Clin Cancer Res,2006,12(9):2817-2825.
[24]PANG PH,CHAN KT,TSE LY,et al.Induction of cytotoxic T cell response against HCA661 positive cancer cells through activation with novel HLA-A ~*0201restricted epitopes[J].Cancer Lett.2007,256(2):178-185.
[25]Vollmer CM Jr,Eilber FC,Butterfield LH,et al.Alpha-fetoprotein specific genetic immunotherapy for hepatocellular carcinoma[J].Cancer Res,1999,59(13):3064-3067.
[26]LIANG CM,YE SL,ZHONG CP,et al.More than chemotaxis:a new antitumor DC vaccine modified by rAAV2-SLC[J].Mol Immunol,2007,44(15):3797-3804.
[27]Li XB,Zhang ZR,Schluesener HJ,et al.Role of exosomes in immune regulation [J].J Cell Mol Med,2006,10(2):364-375
[28]张红梅,张利旺,任军等.树突状细胞—肝癌细胞株HepG2融合细胞来源的exosome抗肝癌效应的实验研究[J].现代肿瘤医学.2006,14(9):1047-1051
[29]Chi KH,Liu SJ,Li CP,Kuo HP,et al.Combination of conformal radiotherapy and intratumorat injection of adoptive dendritic cell immunotherapy in refractory hepatoma[J].J Immunother,2005,28(2):129-135.
[30]Nakamoto Y,Mizukoshi E,Tsuji H,et al.Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma:clinical safety[J].Clin Exp Immunol,2007,147(2):296-305.
